Solid Biosciences Inc. (SLDB): Capital Expenditures
$1.15M
Year ended 2025-12-31
$965.0K
Trailing 12 months to 2026-06-30
-27.4%
3-year compound annual growth
+5.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.15M | +76.3% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $654.0K | -56.8% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $1.51M | -49.8% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $3.02M | +135.4% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $1.28M | +42.5% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $899.0K | -79.5% | 2023-03-23, From 2020-01-01 |
| 2019-12-31 | $4.39M | -43.6% | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | $7.78M | +241.7% | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | $2.28M | +480.6% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $392.0K | n/a | 2019-03-13, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $1.15M | +76.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $532.0K | -77.2% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $4.41M | +15.2% |
| Agenus Inc (AGEN) | 2025-12-31 | $6.0K | -99.0% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $848.0K | +450.6% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $1.49M | +60.5% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $3.83M | -22.8% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $574.0K | -81.6% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $886.0K | -81.1% |
Compare SLDB, DBVT, TCRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗